Mountain View, CA, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, today announced the closing of an equity investment by Boston Scientific Corporation (NYSE: BSX). The additional investment capital will be used to advance the clinical development of the Amaranth FORTITUDE™ drug eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE Mark. In addition, the funding will support continued development of the next generation FORTITUDE™ bioresorbable scaffold, which will have thinner struts than any currently available polymeric bioresorbable scaffold.
Help employers find you! Check out all the jobs and post your resume.
